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INTRODUCTION
Advanced solid tumors, such as mesothelioma, are characterized by heterogeneity and an inability to generate an immune response in an immunocompetent host. [1] [2] [3] [4] These tumors express a variety of antigens; however, they do not stimulate a host immune response. The failure of the host immune system to detect and destroy tumors is attributed to the inability of these tumor antigens to generate a tumor-specific cytotoxic T lymphocyte response. 5 A variety of strategies have been developed to augment the immune system and improve the host response to tumors: introduction of cytokine genes into tumors, overexpression of tumor antigens, modification of APCs to express tumor antigens, and the transfer of co-stimulatory molecules to tumor cells. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Recent studies suggest that the expression of the gene encoding CD40 Ligand (CD40L) may be an effective strategy to enhance the host immune response. 18, 19 CD4 + T cells are essential in the generation of an anti-tumor response. 20 Patients with malignant mesothelioma and other solid tumors are also known to have suppression of CD4 + T lymphocyte function. [21] [22] [23] CD40L has emerged as an important co-stimulatory molecule that may be used to bypass CD4 + T-cells in initiating a CD8 + cytotoxic response. This 33-kDa protein is a member of the tumor necrosis factor (TNF) family and is expressed on the CD4 + T-cells. 24, 25 When CD4 + cells are stimulated, CD40L and CD40 (expressed on the APC) interact and the APC becomes activated. CD40 signaling results in upregulation of the major histocompatability complex (MHC) and co-stimulatory molecule expression is increased in the APC. 1 Furthermore, there is an increased production of cytokines such as IL-12 that facilitates CD8 + T cell activation and result in lysis of tumor cells. 1, 26, 27 Previous studies have demonstrated that ex vivo modification of melanoma and colon cancer cell lines with the CD40L gene results in inhibition of tumor growth. [28] [29] [30] The effect of CD40L appears to be T cell mediated through a CD8 + T cell dependent mechanism. 19 The effectiveness of CD40L immunotherapy appears to be tumor specific with B16 melanoma and CT26 colon cancer cell lines demonstrating an excellent response; whereas, Lewis lung carcinoma cell lines demonstrated less of a response. 18, 19 In this study, we chose to investigate the effectiveness of CD40L gene therapy on malignant mesothelioma using a syngeneic mouse model. To date, there is no data to indicate that CD40L gene therapy may be effective in pulmonary neoplasms. The aim of this study was to determine if the expression of the CD40L gene by these tumors would induce tumor specific cellular immunity, and investigate the effect of this therapy on multi-focal or distant disease. 7 deleted adenovirus encoding the murine CD40L gene. All transgenes were driven by the CMV promoter. The adenoviral vectors were propagated on the 911 cell line, purified on CsCl density gradients, assayed for replication competency, and plaque titered as previously described. Immunocytometry Systems, San Jose, CA). Based on these results, AC29 cells were transfected at an MOI of 10, 50, or 100 using AdCD40L. Forty-eight hours later, CD40L expression was measured by FACS using biotin-anti-mouse CD40L as the primary antibody (Pharmingen, San Diego, CA), followed by StreptAvidin-FITC (Pharmingen). , where "a" is the length of the longer diameter and "b" is the length of the shorter diameter.
Cell Proliferation
Mice were sacrificed when the tumor volume measured 1500 mm 3 or greater or when food and water intake fell below 75% of baseline. Experiments were performed in at least duplicate. In addition, ex vivo therapy was repeated using athymic nude mice.
In vivo Therapy Model. Naïve CBA/J or athymic nude mice were injected with Subsequently, CD3ε (CD3 and chain) biotin-anti-mouse (PharMingen, San Diego, CA), NeutrAvidin Texas Red (Molecular Probes, Eugene, OR), and DAPI were added to the sections. ProLong Antifade Kit was used to mount and preserve the cells for microscopy.
Sections were visualized using deconvolution microscopy as previously described. For the 50 micron sections, CD4 or CD8 (primary antibody) was added to tissue samples followed by Alexa Fluor 488 goat-α-mouse IgG (secondary antibody). SYTOX Orange (Molecular Probes, Eugene, OR) was added to identify the nuclei. ProLong Antifade kit was used to preserve tissue sections for microscopy. Confocal microscopy was utilized to visualize 50 µm sections. A Nikon TE300 microscope (Melville, NY) equipped with a BioRadiance laser scanning system with a krypton/argon laser and dual PMT detectors was used. Imaging was achieved using Laser Sharp 2000 confocal software (BioRad, Hercules, CA).
Tumors were resected two or six days following intratumoral injection with PBS, AdLuc, or AdCD40L to further subjectively characterize MHC class I and II presence and quantitate possible dendritic and CD8 + T-cell infiltration. Tumors were snap frozen in isopentane submerged in liquid nitrogen. Five micron sections were cut using a Leica CM3050S cryostat (Meyer Instruments, Houston, TX). All slides were fixed with -20°C acetone for 10 minutes, thoroughly washed with PBS, and subsequently blocked with 5% goat serum in 1% BSA for 10 minutes. Next, sections were divided for double labeling into CD11c+/MHC II+ and CD8a+/MHC I+ groups. The first primary antibody incubation included biotinylated rat-α-mouse CD11c and hamster-α-mouse H-; BD PharMingen, San Diego, CA) added to their corresponding group of slides at 10 µg/ml for 60 minutes at room temperature. After several washes in PBS, the sections were incubated with secondary detection reagent NeutrAvidin conjugated to Texas Red fluorophore. Next, the sections were washed and the second primary antibody incubation was carried out on both anti-CD11c and anti-MHC I slides with anti-MHC II-FITC and unconjugated anti-CD8a (clone 53-6.7) respectively. The second primaries were also diluted to10 µg/ml and incubated for 60 minutes at room temperature. Finally, all slides were washed and the anti-CD8a was indirectly conjugated to a secondary goat anti-rat IgG Alexa Fluor 488 antibody. All slides were counterstained with blue DAPI nucleic acid dye. Cells were mounted in ProLong and visualized using a Leica DMRXA epifluorescence microscope (Meyer Instruments, Houston, TX). Quantitation was performed for a total of 15 fields using 400X magnification and mask sub-sampling with Slidebook software (Intelligent Imaging Innovations, Denver, CO). A deconvolution algorithm was applied to selected fields using the same software and for presentation purposes only.
Adoptive Transfer. Thirty-five days after receiving indirect therapy or seventeen days after receiving direct therapy CBA/J mice (control tumor volumes were less than 1000 mm 3 ) were sacrificed and spleens were processed through a 70-micron cell strainer to obtain cell suspensions. Cells were enumerated visually using a hemocytometer and Figures 5A and 5B) . This was particularly true of CD8+ T-cells ( Figure 5B ).
Immunohistochemical stains for CD11c were also performed on the resected tumors. A significant increase of CD11c cells was also seen in the tumor bed for mice treated with AdCD40L versus those treated with AdLuc or PBS (p<.05) ( Figure 6A ). This effect was seen both two and six days after intratumoral inoculation with AdCD40L ( Figure 6A ).
Immunohistochemical analysis for the expression of MHC Class I revealed positive staining within the tumor, but no significant change at day 2 or 6 for tumors treated with AdCD40L versus AdLuc or PBS ( Figure 6B ). These data suggest that the anti-tumor effect of AdCD40L is related to a stimulation of the CD8+ T-cell response. This is supported by a lack of effect of intratumoral inoculation with AdCD40L in the athymic nude mouse ( Figure 4B ).
The enhanced CD8+ T-cell effect at day 2 and 6 was also associated with increased serum levels of IL-12 and IFN-γ . At day two, IL-12 levels were significantly increased in AdCD40L treated mice versus AdLuc or PBS mice (310 + 71 vs. 148 + 47 vs. 50 + 35 pg/ml respectively, p< .05). However IL-12 levels fell to near control levels at day 6 in AdCD40L treated mice (45.7 + 30 pg/ml, p=NS). In contrast, IFN-γ levels were significantly increased in AdCD40L treated mice versus AdLuc and PBS mice at both day two (649 + 118 vs. 136 + 78 vs.110 + 95 pg/ml respectively, p < 0.05) and day six (218 + 113 vs. 40 + 23 vs. 0 + 0 pg/ml respectively, p < 0.05). protein expressed on the tumor cells themselves or in intratumoral dendritic cells was able to interact with CD40 found on APCs, which resulted in a systemic IL-12 response and a better CD8+ T-cell response compared to control mice. In support of this systemic immune response, we also observed significant effects on synchronous un-injected tumors which may be due to re-circulation of antigen specific CD8+ T-cells. Moreover, we also observed an increase in CD11c+ cells, presumably dendritic cells after AdCD40L therapy.
In this study, we also demonstrated a dose dependent response for the efficacy of 
